Parkinson's drug tested for apathy, but study stops early
NCT ID NCT05182151
First seen Feb 02, 2026 · Last updated May 18, 2026 · Updated 14 times
Summary
This study looked at whether istradefylline, a drug already approved for motor symptoms in Parkinson's disease, could also improve apathy and motivation. Apathy is a common issue where people lose interest and drive. The study planned to follow 8 participants for 12 weeks, but it was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
MUSC Movement Disorders Program
Charleston, South Carolina, 29425, United States
Conditions
Explore the condition pages connected to this study.